Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.56 |
| ▸ | CES1 | P23141 | 4/20 | 0.56 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | TTR | P02766 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19367869 | 0.82 | CES1 (0.59) | CES2CES1HCAR1CA12CA1 | |
| SCHEMBL4361178 | 0.80 | CES2 (0.56) | CES2CES1HCAR1CA12CA1 | |
| SCHEMBL16581138 | 0.78 | CES2 (0.54) | CES2CES1HCAR1CA12CA1 | |
| SCHEMBL634159 | 0.78 | CES2 (0.54) | CES2CES1HCAR1SLC6A3 | |
| SCHEMBL13604395 | 0.78 | CES2 (0.54) | CES2CES1HCAR1CA12CA1 | |
| SCHEMBL14679128 | 0.78 | CES2 (0.54) | CES2CES1HCAR1CA12CA1 | |
| SCHEMBL976560 | 0.78 | PTPN1 (0.61) | CES2CES1HCAR1PTPN1 | |
| SCHEMBL3093741 | 0.78 | CES2 (0.54) | CES2CES1HCAR1NPC1RAB9A | |
| SCHEMBL16215481 | 0.78 | CES2 (0.54) | CES2CES1HCAR1CA12CA1 | |
| SCHEMBL10373277 | 0.78 | CES2 (0.58) | CES2CES1ACHECA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107207531-B | Fused imidazole derivatives as TGF-beta inhibitors | 里格尔药品股份有限公司 | 2021-05-25 | — | — | CN | disclosed |
| CN-107207531-A | It is used as the imdazole derivatives of the fusion of TGF beta inhibitors | 里格尔药品股份有限公司 | 2017-09-26 | — | — | CN | disclosed |
| CN-103153945-B | 1-oximino-3-phenyl-propanes | HOFFMAN-LA ROCHE LTD. (CH) | 2016-03-02 | — | — | CN | disclosed |
| EP-2593426-B1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | HOFFMANN LA ROCHE (CH) | 2014-08-20 | — | — | EP | disclosed |
| EP-2114906-B1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS | HOFFMANN LA ROCHE (CH) | 2014-08-06 | — | — | EP | disclosed |
| US-8765730-B2 | 1-hydroxyimino-3-phenyl-propanes | Hoffmann-La Roche Inc (US) | 2014-07-01 | — | — | US | disclosed |
| CN-102186921-B | Fluorine-containing copolymer composition and process for production thereof | ASAHI GLASS CO LTD | 2014-01-15 | — | — | CN | disclosed |
| US-8604061-B2 | 2-aminooxazolines as TAAR1 ligands | HOFFMANN-LA ROCHE INC. (US) | 2013-12-10 | — | — | US | disclosed |
| CN-101600700-B | Novel 2-amino oxazolines as TAAR1 ligands for CNS disorders | HOFFMANN LA ROCHE | 2013-08-21 | — | — | CN | disclosed |
| CN-103153945-A | 1-oximino-3-phenyl-propanes | HOFFMANN LA ROCHE | 2013-06-12 | — | — | CN | disclosed |
| US-20050054656-A1 | 5-HT receptor ligands and uses thereof | PFIZER INC | 2005-03-10 | — | — | US | disclosed |
| US-20050032809-A1 | 5-HT receptor ligands and uses thereof | PFIZER INC | 2005-02-10 | — | — | US | disclosed |
| US-20050020604-A1 | 5-HT receptor ligands and uses thereof | PFIZER INC | 2005-01-27 | — | — | US | disclosed |
| US-6825198-B2 | FOR THERAPY OF SEXUAL DISORDER | PFIZER INC | 2004-11-30 | — | — | US | disclosed |
| EP-1401820-A1 | 5-HT RECEPTOR LIGANDS AND USES THEREOF | Pfizer Products Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| EP-1401819-A1 | 5-HT RECEPTOR LIGANDS AND USES THEREOF | Pfizer Products Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030125334-A1 | 5-HT receptor ligands and uses thereof | CHIANG PHOEBE (US) | 2003-07-03 | — | — | US | disclosed |
| US-20030105106-A1 | 5-HT receptor ligands and uses thereof | CHIANG PHOEBE (US) | 2003-06-05 | — | — | US | disclosed |
| WO-2003000663-A1 | 5-HT RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000666-A1 | 5-HT RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032809-A1 | 5-HT receptor ligands and uses thereof | HTR2A, HTR1A, HTR5A | CES2 364/4885CES1 1549/4885HCAR1 142/4885 |
| US-20050020604-A1 | 5-HT receptor ligands and uses thereof | HTR2A, HTR1A, HTR5A | CES2 364/4885CES1 1549/4885HCAR1 142/4885 |
| US-20030105106-A1 | 5-HT receptor ligands and uses thereof | HTR1A, HTR2A, HTR5A | CES2 366/4885CES1 1255/4885HCAR1 162/4885 |
| US-20050054656-A1 | 5-HT receptor ligands and uses thereof | HTR2A, HTR1A, HTR5A | CES2 364/4885CES1 1549/4885HCAR1 142/4885 |
| US-20030125334-A1 | 5-HT receptor ligands and uses thereof | HTR1A, HTR2A, HTR5A | CES2 366/4885CES1 1255/4885HCAR1 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.